Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 26,488 shares at $106.60 ($2.9M) on 2024-03-13, disclosed to the SEC on 2024-03-15.
Scheduled sale ($2.9M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $106.60 | 6,281 | $670K | 23.3% |
| 2 | $106.60 | 6,281 | $670K | 23.3% |
| 3 | $107.66 | 2,300 | $248K | 8.6% |
| 4 | $108.52 | 600 | $65K | 2.3% |
| 5 | $109.50 | 412 | $45K | 1.6% |
| 6 | $110.80 | 3,803 |
| $421K |
| 14.7% |
| 7 | $110.80 | 3,803 | $421K | 14.7% |
| 8 | $111.69 | 1,404 | $157K | 5.5% |
| 9 | $111.69 | 1,404 | $157K | 5.5% |
| 10 | $112.44 | 200 | $22K | 0.8% |
| Total | $108.57 avg | 26,488 | $2.9M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |